Abstract Library

#4391 Clinicopathologic characteristics, therapy and outcomes of gastroenteropancreatic neuroendocrine tumours: A single-centre experience

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are tumours derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract and comprise a heterogeneous family of neoplasms with a wide and complex spectrum of clinical behaviour.

Conference:

Presenting Author:

Authors: Behourah Z, Ahed Messaoud M, Hamidatou K, Megaiz A, Lechar M,

Keywords: Gastroenteropancreatic neuroendocrine tumour, Functional neuroendocrine tumour, Somatostatin analogue (SSA), Chemotherapy,

#4186 The effect of the Covid-19 pandemic on the body composition of patients with gastroenteropancreatic neuroendocrine tumors using a somatostatin analogue

Introduction: The Covid-19 pandemic and its restrictions had a negative impact on the general population. Due to lockdowns, food intake increased and exercise decreased. This led to weight gain and changes in body composition. Hospitals reviewed patients (pts) remotely. The effect of the Covid-19 pandemic has not been described in pts with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogue (SSA).

Conference:

Presenting Author: Clement D

Authors: Clement D, Brown S, Dolly S, Mestre-Alagarda C, Giovos G,

Keywords: GEP-NET, SSA, malnutrition, Covid-19 pandemic,

#4144 Phase Ib portion of the ACTION-1 Phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings

Introduction: RYZ101 (225Ac-DOTATATE) is an alpha-emitting radiopharmaceutical in development for SSTR2+ solid tumors.

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Ulaner G, Halperin D, Mehr S, Kotiah S,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Somatostatin analogue therapy, Somatostatin receptor positive, RYZ101,

#3624 Clinical outcomes of everolimus (EVE) for patients with advanced rectal neuroendocrine tumors (ARNETs) – A single-institutional retrospective study

Introduction: RADIANT-4 has established EVE as one of the standard-of-care for advanced NET G1–2 of gastrointestinal or lung origin, with a trend of a poorer efficacy of EVE in ARNET (median progression-free survival [PFS] of EVE: 17.3 months in advanced midgut NETs vs 7.4 months in the ARNETs). Little is known about the clinical outcomes of EVE for ARNET G1–2 and G3 in the real-world setting.

Conference:

Presenting Author: Kim Y

Authors: Kim Y, Hirano H, Yamamoto S, Okita N, Shoji H,

Keywords: everolimus, rectal neuroendocrine tumor,

#3515 PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy

Introduction: Long-acting (LA) SSA therapy is a common long-term treatment for NETs, but real-world data on patients’ injection experience using the latest LA SSA designs/formulations are limited.

Conference:

Presenting Author: O'Toole D

Authors: O'Toole D, Prebtani A, Webb S, Houchard A, Gueguen D,

Keywords: acromegaly, injection site pain, lanreotide autogel/depot, neuroendocrine tumor, octreotide long-acting release syringe, patient survey,